Sopharma Group has acquired two pharmaceutical products in Poland
Sopharma Group has acquired Coffepirine and Kopiryna, two highly recognized medicines to treat headache. The acquisition will further expand the market presence of Sopharma Group in the Polish market and support the promising potential of the two pharmaceutical drugs.
Sopharma Group is a leading producer and distributor of healthcare products in the CEE, with a vertically integrated business model running through the whole value chain, with its own R&D, manufacturing and wholesale and retail distribution. The company is present in 33 countries and has a portfolio consisting of more than 200 products.
Coffepirine and Kopiryna are OTC analgesics with APIs based on a combination of acetylsalicylic acid and caffeine, which have helped the Polish public to treat headaches for decades. The drugs are developed and manufactured by Medicofarma, a well-known Polish pharmaceuticals company.
Medicofarma is a pharmaceutical manufacturing company focusing on contract manufacturing of pharmaceuticals, medicinal products and dietary supplements. The company has a modern factory equipped with state-of-the-art technology and meets all GMP requirements.
Oaklins’ team in Bulgaria acted as buy-side advisor to Sopharma Group, leading the transaction process, deal structuring and negotiations, and assisting throughout the acquisition process.
Contacter l'équipe de la transaction
Transactions connexes
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
En apprendre plusbioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
En apprendre plusSLT has been acquired by Indutrade
SLT S.r.l. has been acquired by Indutrade AB and will be integrated into the group’s life science business area. The transaction is Indutrade’s fifth acquisition in 2025 and is expected to have a marginally positive impact on the group’s earnings per share.
En apprendre plus